A Clinical Trial of TQC2938 Injection in Healthy Adult Subjects
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The study is designed in two phases: single-dose administration and multiple-dose administration. A randomized, double-blind, placebo-controlled trial design was used to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of TQC2938 injection in healthy adults.
Phase:
PHASE1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.